Trial Outcomes & Findings for High Water Intake to Slow Progression of Polycystic Kidney Disease (NCT NCT00784030)

NCT ID: NCT00784030

Last Updated: 2016-04-06

Results Overview

Urine cAMP (UcAMP) concentration and urine osmolality UOsm) were measured pre- and post-water loading: with 2.5L over 2 hours

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

23 participants

Primary outcome timeframe

pre- and post-water loading (2 hours)

Results posted on

2016-04-06

Participant Flow

Participant milestones

Participant milestones
Measure
Polycystic Kidney Disease (PKD) Patients
Patients who present with polycystic kidney disease (PKD)
Healthy Patients
Overall Study
STARTED
13
10
Overall Study
COMPLETED
13
10
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

High Water Intake to Slow Progression of Polycystic Kidney Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Polycystic Kidney Disease (PKD) Patients
n=13 Participants
Healthy Patients
n=10 Participants
Total
n=23 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
13 Participants
n=5 Participants
10 Participants
n=7 Participants
23 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Female
8 Participants
n=5 Participants
7 Participants
n=7 Participants
15 Participants
n=5 Participants
Sex: Female, Male
Male
5 Participants
n=5 Participants
3 Participants
n=7 Participants
8 Participants
n=5 Participants

PRIMARY outcome

Timeframe: pre- and post-water loading (2 hours)

Population: Number of participants was deemed to be adequate for the purposes of this pilot study

Urine cAMP (UcAMP) concentration and urine osmolality UOsm) were measured pre- and post-water loading: with 2.5L over 2 hours

Outcome measures

Outcome measures
Measure
Polycystic Kidney Disease Patients
n=13 Participants
Patients with Autosomal Dominant Polycystic Kidney Disease
Healthy Controls
n=10 Participants
Healthy Controls
Change in Urine cAMP Concentration and Urine Osmolality (UOsm)
-2.6 fold change in cAMP/UOsm (umol/UOsm)
Standard Error 0.2
-2.0 fold change in cAMP/UOsm (umol/UOsm)
Standard Error 0.1

Adverse Events

Polycystic Kidney Disease Patients

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Healthy Controls

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Irina Barash

New York University School of Medicine

Phone: 212.263.5851

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place